Transporters and drug therapy: Implications for drug disposition and disease

被引:338
作者
Ho, RH
Kim, RB
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pediat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA
关键词
D O I
10.1016/j.clpt.2005.05.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response. Most studies to date have focused on the contribution of drug-metabolizing enzymes to the drug disposition process. However, over the past decade, it has become increasingly apparent that carrier-mediated processes, or transporters, also play critical roles in the overall disposition of numerous drugs in clinical use. In addition to their roles in xenobiotic transport, drug transporters often mediate important physiologic functions via transport of endogenous substrates such as amino acids, bile acids, and hormones that are critical for maintenance of normal homeostasis. In this review we focus on the emerging field of transporter proteins in relation to the drug disposition process, with particular emphasis on clinical implications of transporters to drug-drug interactions and subsequent development of adverse effects, inter-individual variability in drug response, and human disease.
引用
收藏
页码:260 / 277
页数:18
相关论文
共 148 条
  • [1] Allen JD, 2002, MOL CANCER THER, V1, P427
  • [2] Role of transport proteins in drug absorption, distribution and excretion
    Ayrton, A
    Morgan, P
    [J]. XENOBIOTICA, 2001, 31 (8-9) : 469 - 497
  • [3] Intrahepatic cholestasis of pregnancy: A French prospective study
    Bacq, Y
    Sapey, T
    Brechot, MC
    Pierre, F
    Fignon, A
    Dubois, F
    [J]. HEPATOLOGY, 1997, 26 (02) : 358 - 364
  • [4] BASIN KS, 1991, J RHEUMATOL, V18, P609
  • [5] The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
    Bodzioch, M
    Orsó, E
    Klucken, T
    Langmann, T
    Böttcher, L
    Diederich, W
    Drobnik, W
    Barlage, S
    Büchler, C
    Porsch-Özcürümez, M
    Kaminski, WE
    Hahmann, HW
    Oette, K
    Rothe, G
    Aslanidis, C
    Lackner, KJ
    Schmitz, G
    [J]. NATURE GENETICS, 1999, 22 (04) : 347 - 351
  • [6] Mechanisms of hepatic transport of drugs: Implications for cholestatic drug reactions
    Bohan, A
    Boyer, JL
    [J]. SEMINARS IN LIVER DISEASE, 2002, 22 (02) : 123 - 136
  • [7] The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines
    Bortnick, AE
    Rothblat, GH
    Stoudt, G
    Hoppe, KL
    Royer, LJ
    McNeish, J
    Francone, OL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (37) : 28634 - 28640
  • [8] Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
    Boyd, RA
    Stern, RH
    Stewart, BH
    Wu, XC
    Reyner, EL
    Zegarac, EA
    Randinitis, EJ
    Whitfield, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) : 91 - 98
  • [9] MDR1 Ala893 polymorphism is associated with inflammatory bowel disease
    Brant, SR
    Panhuysen, CIM
    Nicolae, D
    Reddy, DM
    Bonen, DK
    Karaliukas, R
    Zhang, LL
    Swanson, E
    Datta, LW
    Moran, T
    Ravenhill, G
    Duerr, RH
    Achkar, JP
    Karban, AS
    Cho, JH
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (06) : 1282 - 1292
  • [10] Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
    Brooks-Wilson, A
    Marcil, M
    Clee, SM
    Zhang, LH
    Roomp, K
    van Dam, M
    Yu, L
    Brewer, C
    Collins, JA
    Molhuizen, HOF
    Loubser, O
    Ouelette, BFF
    Fichter, K
    Ashbourne-Excoffon, KJD
    Sensen, CW
    Scherer, S
    Mott, S
    Denis, M
    Martindale, D
    Frohlich, J
    Morgan, K
    Koop, B
    Pimstone, S
    Kastelein, JJP
    Genest, J
    Hayden, MR
    [J]. NATURE GENETICS, 1999, 22 (04) : 336 - 345